Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.

Rashi KalraChing Hui ChenJunkai WangAhmad Bin SalamLacey Elizabeth DobroleckiAlaina LewisChristina SallasClayton C Yates Carolina GutierrezBalasubramanyam KaranamMeenakshi Anurag Bora Lim Matthew J Ellis Shyam M Kavuri

Published in: Cancer research (2022)

Evaluation of the functional impact of HER2 mutations on therapy-induced resistance and metastasis identifies robust antitumor activity of poziotinib and supports the clinical evaluation of poziotinib in ER+ HER2 mutant breast cancer.

Keyphrases

wild type
high glucose
genome wide
gene expression
drug induced
stem cells
oxidative stress
estrogen receptor
breast cancer cells
mesenchymal stem cells
young adults
smoking cessation